C4 Therapeutics (CCCC) News
NASDAQ: CCCCHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
2.48+0.04 (+1.64%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CCCC news summary
We found 5 recent headlines mentioning C4 Therapeutics (CCCC): 0 in the past week and 5 in the past 30 days, most often from GlobeNewswire, Nasdaq. For price context, CCCC is up 1.64% at $2.48. The most recent story, "C4 Therapeutics Reports Third Quarter 2026 Financial Results", was published by Nasdaq on Nov 5, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest C4 Therapeutics headlines
- C4 Therapeutics Reports Third Quarter 2026 Financial ResultsC4 Therapeutics, Inc. reported its financial results for the third quarter ended September 30, 2026. Total revenue for the third quarter of 2026 was $8.5 million, compared to $11.2 million for the…Nasdaq
- C4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business HighlightsCemsidomide Phase 2 MOMENTUM Trial On Track to Complete Enrollment in 1Q 2027 with Initial ORR Data Expected in 2H 2027GlobeNewswire
- C4 Therapeutics to Participate in Upcoming November Investor ConferencesWATERTOWN, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD)…GlobeNewswire
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)WATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science,…GlobeNewswire
- C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue DegradersDEL Technology Integrating C4T’s Cereblon Library Can Rapidly Advance Projects Into Hit-To-Lead Stage DEL Technology Integrating C4T’s Cereblon Library Can Rapidly Advance Projects Into Hit-To-Lead…GlobeNewswire